Targeting Cancer Cells using 3-bromopyruvate for Selective Cancer Treatment

Cancer treatment deserves more research efforts despite intensive conventional treatment modalities for many types of malignancies. Metastasis and resistance to chemotherapy and radiotherapy receive a lot of global research efforts. The current advances in cancer biology may improve targeting the critical metabolic differences that distinguish cancer cells from normal cells. Cancer cells are highly glycolytic for energy production, exhibit the Warburg effect, establish aggressive acidic microenvironment, maintain cancer stem cells, exhibit resistance to chemotherapy, have low antioxidant systems but different ΔΨm (delta psi, mitochondrial transmembrane potential), express P-glycoprotein for multidrug resistance, upregulate glucose transporters and monocarboxylate transporters and are under high steady-state reactive oxygen species conditions. Normal cells differ in all these aspects. Lactate produced through the Warburg effect helps cancer metastasis. Targeting glycolysis reactions for energy production in cancer cells seems promising in decreasing the proliferation and metastasis of cancer cells. 3-bromopyruvate makes use of cancer biology in treating cancer cells, cancer stem cells and preventing metastasis in human cancer as discussed in this review. Updated advances are analyzed here, which include research analysis of background, experience, readings in the field of cancer biology, oncology and biochemistry.

• Publication year

  2016

• Venue

  Saudi Journal of Medicine and Medical Sciences

• Publication date

  2016-11-16

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.4103/1658-631X.194253PMID 30787746PMCID 6298280
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The cytotoxicity of 3-bromopyruvate in breast cancer cells depends on extracellular pH.

  2015cited by this paper
• The antitumor agent 3-bromopyruvate has a short half-life at physiological conditions.

  2014cited by this paper
• Monocarboxylate transporters as targets and mediators in cancer therapy response.

  2014cited by this paper
• The Reversal Effects of 3-Bromopyruvate on Multidrug Resistance In Vitro and In Vivo Derived from Human Breast MCF-7/ADR Cells

  2014cited by this paper
• Safety and outcome of treatment of metastatic melanoma using 3-bromopyruvate: a concise literature review and case study

  2014cited by this paper
• Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine

  2014cited by this paper
• The energy blocker inside the power house: mitochondria targeted delivery of 3-bromopyruvate

  2014cited by this paper
• Metabolic vulnerabilities in endometrial cancer.

  2014cited by this paper
• Cancer cell metabolism: implications for therapeutic targets

  2013cited by this paper
• Altered energy metabolism in cancer

  2013cited by this paper
• Tumor-derived lactate and myeloid-derived suppressor cells

  2013cited by this paper
• How does the metabolism of tumour cells differ from that of normal cells

  2013cited by this paper
• D-Amino acid oxidase-induced oxidative stress, 3-bromopyruvate and citrate inhibit angiogenesis, exhibiting potent anticancer effects

  2012cited by this paper
• 3-Bromopyruvate antagonizes effects of lactate and pyruvate, synergizes with citrate and exerts novel anti-glioma effects

  2012influential reference
• A translational study “case report” on the small molecule “energy blocker” 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside

  2012cited by this paper
• Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion.

  2012cited by this paper
• 3-bromopyruvate: Targets and outcomes

  2012cited by this paper
• Enhancement of hexokinase II inhibitor-induced apoptosis in hepatocellular carcinoma cells via augmenting ER stress and anti-angiogenesis by protein disulfide isomerase inhibition

  2012cited by this paper
• PI3K‐independent AKT activation in cancers: A treasure trove for novel therapeutics

  2012cited by this paper
• Inhibition of hexokinase leads to neuroprotection against excitotoxicity in organotypic hippocampal slice culture

  2011cited by this paper
• Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-κB/IL-8 pathway that drives tumor angiogenesis.

  2011cited by this paper
• Glycolysis Inhibition Inactivates ABC Transporters to Restore Drug Sensitivity in Malignant Cells

  2011cited by this paper
• D-amino acid oxidase gene therapy sensitizes glioma cells to the antiglycolytic effect of 3-bromopyruvate

  2011influential reference
• Therapeutic strategies by modulating oxygen stress in cancer and inflammation.

  2009cited by this paper
• Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer

  2009cited by this paper
• Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death.

  2009cited by this paper
• Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate.

  2009cited by this paper
• Increased levels of superoxide and H2O2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation.

  2009cited by this paper
• Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?

  2009cited by this paper
• Hypoxia, HIF1 and glucose metabolism in the solid tumour

  2008cited by this paper
• Tumor-Secreted Lactic Acid Promotes IL-23/IL-17 Proinflammatory Pathway1

  2008cited by this paper
• Tumor metabolism: cancer cells give and take lactate.

  2008cited by this paper
• Cell Cycle Regulation by Oncogenic Tyrosine Kinases in Myeloid Neoplasias: From Molecular Redox Mechanisms to Health Implications

  2008cited by this paper
• Voltage dependent anion channels (VDACs): a brief introduction with a focus on the outer mitochondrial compartment’s roles together with hexokinase-2 in the “Warburg effect” in cancer

  2008cited by this paper
• Mitochondrial membrane permeabilization in cell death.

  2007cited by this paper
• Models of reactive oxygen species in cancer.

  2007cited by this paper
• Lactate dehydrogenase as a prognostic factor for survival time of terminally ill cancer patients: a preliminary study.

  2007cited by this paper
• Inhibitory effect of tumor cell-derived lactic acid on human T cells.

  2007cited by this paper
• Coping with stress: multiple ways to activate p53

  2007cited by this paper
• p53 Regulates Mitochondrial Respiration

  2006cited by this paper
• Glucose metabolism and cancer.

  2006cited by this paper
• Mitochondrial mutations in cancer

  2006cited by this paper
• Oxidative and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis

  2006cited by this paper
• Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism

  2006cited by this paper
• Tumor-derived lactic acid modulates dendritic cell activation and antigen expression.

  2006cited by this paper
• Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance.

  2006cited by this paper
• Acid-mediated tumor invasion: a multidisciplinary study.

  2006cited by this paper
• Hexokinase II: Cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria

  2006cited by this paper
• The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis

  2005cited by this paper
• Regulation of reactive oxygen species, DNA damage, and c-Myc function by peroxiredoxin 1

  2005cited by this paper
• CuZnSOD deficiency leads to persistent and widespread oxidative damage and hepatocarcinogenesis later in life

  2005cited by this paper
• Lactate in solid malignant tumors: potential basis of a metabolic classification in clinical oncology.

  2004cited by this paper
• Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP.

  2004cited by this paper
• Why do cancers have high aerobic glycolysis?

  2004cited by this paper
• PI3K-Akt pathway: Its functions and alterations in human cancer

  2004cited by this paper
• Mitochondrial Bound Hexokinase Activity as a Preventive Antioxidant Defense

  2004cited by this paper
• The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models.

  2003cited by this paper
• Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function

  2003cited by this paper
• Reactive oxygen species in oncogenic transformation.

  2003cited by this paper
• Hypoxia reduces CD80 expression on monocytes but enhances their LPS-stimulated TNF-alpha secretion.

  2003cited by this paper
• Necrosis: a specific form of programmed cell death?

  2003cited by this paper
• Harper's Illustrated Biochemistry

  2003cited by this paper
• c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability.

  2002cited by this paper
• Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion

  2002cited by this paper
• The protein kinase B/Akt signalling pathway in human malignancy.

  2002cited by this paper
• Molecular imaging of cancer with positron emission tomography

  2002cited by this paper
• ROS, stress‐activated kinases and stress signaling in cancer

  2002cited by this paper
• Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer.

  2001cited by this paper
• Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase.

  2001cited by this paper
• Mammalian hexokinases and their abnormal expression in cancer.

  2000cited by this paper
• Causes and consequences of tumour acidity and implications for treatment.

  2000cited by this paper
• High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers.

  2000cited by this paper
• Role of plasma membrane transporters in muscle metabolism.

  2000cited by this paper
• c-Myc transactivation of LDH-A: implications for tumor metabolism and growth.

  1997cited by this paper
• Mitogenic Signaling Mediated by Oxidants in Ras-Transformed Fibroblasts

  1997cited by this paper
• Pyruvate Protects Neurons against Hydrogen Peroxide-Induced Toxicity

  1997cited by this paper
• Production of large amounts of hydrogen peroxide by human tumor cells.

  1991cited by this paper
• The membrane-bound hexokinase as a potential marker for malignancy in human gliomas.

  1990cited by this paper
• Positron emission tomographic evaluations in the diagnosis and therapy of multifocal glioblastoma. Report of a pediatric case.

  1985cited by this paper
• Acetyl coenzyme A and acetylcholine in slices of rat caudate nuclei incubated in the presence of metabolic inhibitors.

  1981cited by this paper
• Role of superoxide dismutase in cancer: a review.

  1979cited by this paper
• Bromopyruvate as an affinity label for baker's yeast flavocytochrome b2. Kinetic study of the inactivation reaction.

  1977cited by this paper
• Glycolysis and pasteur effect in rat reticulocytes.

  1973cited by this paper
• [Origin of cancer cells].

  1956cited by this paper
• On the origin of cancer cells.

  1956cited by this paper
• On respiratory impairment in cancer cells.

  1956cited by this paper
• On respiratory impairment in cancer cells.

  1956cited by this paper
• Observations on the carbohydrate metabolism of tumours.

  year unknowncited by this paper

• The cubosome-based nanoplatforms in cancer therapy: Seeking new paradigms for cancer theranostics.

  2023cites this paper
• Stimuli-responsive cancer nanomedicines inhibit glycolysis and impair redox homeostasis.

  2023cites this paper
• Cancer on-target: Selective enhancement of 3-bromopyruvate action by an electromagnetic field in vitro.

  2022cites this paper
• Extracellular acidity in tumor tissue upregulates programmed cell death protein 1 expression on tumor cells via proton‐sensing G protein‐coupled receptors

  2021cites this paper
• Delphinidin Increases the Sensitivity of Ovarian Cancer Cell Lines to 3-bromopyruvate

  2021cites this paper
• Overcoming Chemoresistance: Altering pH of Cellular Compartments by Chloroquine and Hydroxychloroquine

  2021influential citation
• Cancer cell metabolism: rewiring the mitochondrial hub.

  2020cites this paper
• Dual inhibition of glycolysis and autophagy as a therapeutic strategy in the treatment of Ehrlich ascites carcinoma

  2020cites this paper
• Physicochemical and in vitro cytotoxicity studies of inclusion complex between gemcitabine and cucurbit[7]uril host.

  2020cites this paper
• Diverse Stakeholders of Tumor Metabolism: An Appraisal of the Emerging Approach of Multifaceted Metabolic Targeting by 3-Bromopyruvate

  2019cites this paper
• Stoichiometry and thermodynamics of gemcitabine and cucurbituril Q7 supramolecular complexes in high acidic aqueous solution

  2019cites this paper
• Oxidative Stress Therapy for Cancer Using Glycolysis Inhibitors: Towards Improving Therapeutic Outcomes

  2018cites this paper
• 3-bromopyruvate as a Promising Treatment for Hematological Cancer

  2018cites this paper